Background: The ß2-adrenergic receptors are cell surface receptors playing a central role in the pharmacological targeting asthma and chronic obstructive pulmonary disease (COPD). Recent studies suggest that patients who are homozygous for one of the two important polymorphisms of the ß2-adrenergic receptor (ADRB2) gene at codon 16 (arginine to glycine) and 27 (glutamine to glutamate) may have a reduced response to ß2-agonists. Since smoking patients who are Gly16 homozygotes have an increased risk of airway obstruction we hypothesized that ß2-adrenoreceptor gene polymorphisms may be also a cofounder for COPD development and disease severity. Methods: We investigated 190 COPD patients and 172 healthy volunteers in a case-control study. DNA was isolated from whole blood and ß2-AR gene polymorphisms Arg/Gly16 and Gln/Glu27 were determined using allele-specific polymerase chain reaction (PCR). Results: In COPD patients with Gly/Gly16 was found more frequently than in healthy smokers (29.47% COPD versus 18.18% controls, p ¼ 0.026). All other gene polymorphisms of the ADRB2 gene at codon 16 were equally distributed between groups. ß2-adrenoreceptor gene polymorphisms were neither a cofounder for COPD exacerbations (! 3 hospitalizations within the last 3 years) nor for disease severity (FEV1 30% predicted). Conclusion: Our study suggests that the Gly16 allele of the ß2-AR gene predisposes to COPD development but not for exacerbation rates and disease severity. In contrast, Gln/Glu27 polymorphism was irrelevant in our COPD cohort.
Introduction
Chronic obstructive lung disease (COPD) is an enormous cause of global morbidity and mortality. Cigarette smoking is clearly the main risk factor for COPD, but only 10-20% of chronic heavy smokers will develop symptoms of airway obstruction [Nowak et al. 2005; Davis and Novotny, 1989 ]. Thus, it has been postulated that genetic factors may be involved in these differences of susceptibility [Joos et al. 2003 ]. Although familial aggregation could be due to environmental factors, there is considerable evidence in favor of a genetic basis of COPD because -among other reasons -the prevalence of COPD and similarity in lung function decrease with increased genetic distance [Hallberg et al. 2008; Silverman et al. 1998 ]. The genes that contribute to the development of COPD may do so via several different mechanisms. The most investigated genetic determinant, which has been recognized for over 30 years, is the inherited severe deficiency of alpha1-antitrypsin. However, twin studies and segregation analyses in relatives of COPD patients have also demonstrated familial aggregation of reduced lung function, which were not linked to the alpha1-antitrypsin genes [Sampsonas et al. 2006; Joos et al. 2002] . Other familial factors identified by these studies may therefore contribute to the level of lung function irrespective of susceptibility to the detrimental effects of cigarette smoke [Silverman et al. 2002] . Family studies suggest that certain genetic risk factors only predispose to COPD in individuals who are smoking [Silverman et al. 1998 ]. Some genes may lead to the development of airflow obstruction by loss of elastic recoil resulting in emphysema, whereas others contribute to chronic airway inflammation resulting in airway narrowing or the lack of response to medications such as ß2-sympathomimetics or inhaled corticosteroids. It has also been hypothesized that genetic alteration of the receptor genes may contribute to disease severity [Joos et al. 2002] .
Beta-adrenergic receptors (ADRBs) are cell surface receptors that play a central role in the sympathetic nervous system [Taylor, 2007] . Pharmacological targeting of ß2-adrenergic receptor represents a widely used therapeutic approach for asthma and COPD. Genetic variation in ADRB2 has been linked to the asthma phenotype. Polymorphisms in ß2 adrenergic receptor gene were found to be associated with asthma severity [Palmer et al. 2006; Weir et al. 1998; Reihsaus et al. 1993] , occurrence of nocturnal asthma [Yin et al. 2006; Turki et al. 1995] , susceptibility to cigarettes smoke [Yin et al. 2007; Zhang et al. 2007] , IgE levels in asthmatic families [Dewar et al. 1997] , poor responsiveness to ß2-adrenergic drugs such as salmeterol or albuterol [Giubergia et al. 2008; Hizawa et al. 2007; Wechsler et al. 2006; Israel et al. 2004; Lipworth et al. 2000a Lipworth et al. , 2000b Lipworth et al. , 1999 Kotani et al. 1999; Ramsay et al. 1999] , susceptibility to bronchodilator desensitization [Tan et al. 1997 ] and a greater systemic response to shortacting ß-adrenergic drugs [Lee et al. 2004 ]. However, genetic linkage to bronchial hyperresponsiveness, the risk of developing allergic diseases or asthma per se, and responsiveness to short-acting ß2-adrenergic drugs on regular basis (but not on an as-needed basis) or long-acting ß2-adrenergic dugs when used in combination with inhaled corticosteroids is discussed controversially [Bleeker et al. 2006; Kim et al. 2006; Taylor et al. 2005; Israel et al. 2000; Lipworth et al. 1999; Dewar et al. 1998 ]. Several polymorphisms of the ß2-AR gene have been identified [Taylor, 2007; Green et al. 1995 Green et al. , 1994 Reihsaus et al. 1993] . In particular, the amino acid substitutions from Arg!Gly at position 16, from Gln!Glu at position 27, and from Thr!Ile at position 164 are known to affect receptor function in vitro. Cells expressing the Ile164 polymorphism lead to significantly less coupling of the ß 2 AR receptor to adenyl cyclase than wild-type cells [Green et al. 1993] . Polymorphisms in position 16 and 27 are more common [Weir et al. 1998 ]. The Gly 16/Gln27 and Gly16/Glu27 variants show significantly more agonist-promoted receptor downregulation than cells expressing the Arg16/Gln27 variant in vitro [Green et al. 1995 [Green et al. , 1994 [Green et al. , 1993 .
Most studies on ß 2 -polymorphisms had been performed in asthmatics and only a few are available on COPD. Once an association of ß2-adrenergic receptor gene polymorphisms with cigarette smoking have been postulated [Yin et al. 2007; Zhang et al. 2007] , we hypothesized that there could exist a linkage of these polymorphisms with COPD outcome and disease severity.
Materials and methods

Study subjects
One-hundred-and-ninety patients with COPD according GOLD-definition grade I-IV [GOLD Executive Committee, 2007] and 172 healthy volunteers were recruited in two centers: in the St. Georg Medical Center, Robert-Koch-Hospital (Leipzig, Germany) and in a private practice specialized for pulmonary medicine within the same region. All patients had a history of chronic or recurrent productive cough for ! 2 years and decreased maximum expiratory flow that has been slowly progressive and irreversible according to medical examinations from the referred physician in private practice or our own accounts. The including criteria in the hospital were as follows:
(1) ! three exacerbations within 1 year, as defined (a) by the GOLD initiative [GOLD Executive Committee, 2007] , and (b) the requirement of hospital treatment with systemic corticosteroids and/ or antibiotics; (2) FEV 1 570% predicted and FEV 1 / FVC ratio570%; (3) reversibility after the inhalation of fenoterol MDI (40 mg) and ipratropiumbromide (40 mg) FEV 1 512% and 5200 ml; (4) ! 20 pack years cigarette consumption; (5) known allergies (history and tested by skin prick test); and (6) patient consent for participation.
All of the patients in the hospital were treated alike, receiving methylxanthine, tiotropiumbromide, inhaled long-acting ß2-agonists, inhaled short-acting ß2-agonists as needed, and 100 mg prednisolone per day which was tapered off within 2 weeks. Five COPD patients with acute exacerbations were tapered off oral prednisolone after 4 weeks.
COPD patients were recruited from the private practice specialized for pulmonary medicine when they fulfilled the following criteria: (1) known to the pulmonary physician for at least Therapeutic Advances in Respiratory Disease 3 (1) 2 years; (2) stable disease conditions (no exacerbations requiring systemic prednisolone, visit at a hospital/emergency room/pulmonary physician because of worsening of dyspnea within the last 2 years); (3) FEV 1 /FVC ratio 570%; (4) reversibility after the inhalation of Fenoterol MDI (40 mg) and ipratropiumbromide (40 mg) FEV 1 512% and 5200 ml; (5) ! 20 pack years cigarette consumption, (6) known allergies (history and tested by skin prick test) and (7) patient consent to participate in the study.
To control our results with normal population data we compared our findings with normal age-matched volunteers with no known medical illness or family disorders and were taking no medication. Most of them were smokers to avoid nonsmoking as a confounding factor. Exclusion criteria were any other disease of the airways or the lung parenchyma, particularly COPD and asthma, and the refusal to give written consent of voluntary participation.
All patients and the volunteers were from Caucasian descent. At enrolment the patients were divided into two groups: 66 COPD patients with frequent exacerbations and 124 COPD patients in stable condition (see Table 1 ). Smoking history, disease development according to the patient's report, lung function and blood gas analysis were recorded. The study was approved by the Ethics Committee of the state of Saxony, Dresden, Germany. ß 2 -adrenoceptor genotyping Genomic DNA from 9 ml peripheral whole blood was prepared by standard phenol/chloroform extracting procedures [Ho et al. 2001 ]. Polymorphisms of the ß2-adrenoceptor coding block were delineated using an allele-specific polymerase chain reaction (PCR) approach.
Allele-specific PCR was performed to assess polymorphisms at nucleic acids 46 and 79 resulting in changes in the encoded amino acids at positions 16 and 27 of the receptor protein.
These variations have been shown to have an effect on asthma phenotype [Zhang et al. 2007; Liggett, 2000; Dewar et al. 1997; Hall et al. 1995] and COPD respectively [Ho et al. 2001 ]. Genotypes are abbreviated as Arg16, Gly16, Gln27, Glu27. A PCR product which includes the region of the ß2AR-16 and the ß2AR-27 polymorphism were generated using the primers 5 0 -GCCTTCTTGCTGGCACCCCAT-3 0 and 5 0 -CAGACGCTCGAACTTGGCCATG-3 0 [Moore et al. 2000 ]. PCR reactions were carried out in 50 ml containing 10 ml (ffi 120 ng) of genomic DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each deoxynucleotide triphosphates, 20 pmol of each primer and 2.5 units of HotStar Taq DNA polymerase (Qiagen). The reaction consisted of an initial denaturation at 95 C for 15 min, followed by 35 cycles: 95 C for 1 min, 60 C for 1 min and 72 C for 1 min, then a final extension for 5 min at 72 C. The size of the generated product was 168 bp. Genotyping of the polymorphisms at positions 16 and 27 was performed by restriction enzyme digestion of PCR products as previously described [Martinez et al. 1997 ] with some modifications. Briefly, 8 ml of the 50 ml PCR product was digested at an introduced restriction site to determine the genotype encoding amino acid 16 with 2 U of Nco I (New England BioLabs) in 6 ml of 25 mM potassium acetate, 10 mM Tris acetate (pH 7.9), 5 mM magnesium acetate, 0.5 mM DTT, and 16.7 mM MgCl 2 at 37 C for 2 h. The 5 0 -primer creates a NcoI restriction enzyme site on PCR product generated from the Gly-16 allele but not from the Arg-16 allele. The 3 0 -primer contains a complete restriction site and thus NcoI digests the PCR product from both alleles, which served as a control for assessing whether digestion was complete (Figure 1 ). Six microliters of the same PCR product was digested with 2 U of FnuH I (New England BioLabs) to identify the presence or absence of a naturally occurring restriction site at the locus encoding amino acid 27. The reaction was completed in 4 ml 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol at 37 C for 2 h. The restriction digests were electrophoresed on 4% NuSieve (BioWhittaker, Rockland Maine) agarose gels and visualized with ethidium bromide staining and ultraviolet illumination (Figures 1 and 2) . Fifty samples were selected at random for DNA sequencing to confirm the correctness of genotyping protocol.
Statistical analysis
The allele frequencies and allelic associations with FEV 1 as parameter of disease severity were analyzed using the 2 test for 2 Â 2 or 3 Â 2 contingency tables and the Fishers's exact test.
All tests were performed using the SigmaStat Statistical software version 2.0 (SPSS Science). Haplotype frequencies were estimated using the expectation maximization (EM) algorithm. The Arlequin software package (Version 3.0) was used to test the linkage disequilibrium and the Hardy-Weinberg equilibrium.
Results
Baseline characteristics of COPD-patients and healthy volunteers are summarized in Table 1 .
For both polymorphisms, the overall observed distribution of homozygotes and heterozygotes conformed to expectations based on Hardy-Weinberg analysis. There was a strong linkage disequilibrium (D 0 ¼ 100%, p50.00001) between alleles at the two loci. Associations between the Gly16 and Glu27 alleles and between the Arg16 and Gln27 alleles was inferred with the estimation of haplotype frequencies using the expectation maximization (EM) algorithm (Table 2) . There was a significant difference in the haplotype frequency between COPD patients and healthy volunteers (Figure 3) . No subjects were simultaneous homozygote for both Arg16 and Glu27. Many of the healthy subjects carried the Arg16/ Gln27 haplotype (30/172, 17,44%) and only a few had Gly16/Gln27 (10/172, 5,81%). In contrast, the three haplotypes were randomly distributed among COPD patients. Figure 3 demonstrates the distribution pattern of Arg/Gly16. Comparing COPD patients and healthy smokers a significant difference in ß2-AR genotype frequency was found at position 16: homozygote Gly/Gly was more frequent (p ¼ 0.026 with Fisher's exact test) in COPD (29.47%) than in normals (18.18%) and vice versa for Arg/Arg (21.58% versus 18.79%). Allele frequencies of Glu27 and Gln27 were not significantly different between the two groups (0.41 and 0.59). Glu/Gln heterozygous genotype was equivalent distributed among COPD patients and healthy volunteers (46.84% versus 53.79%, p ¼ 0.433) while Gln/ Gln frequency was as a trend more frequent (35.79% versus 32.58%, p ¼ 0.07). Allele frequency was uniformed distributed in the population (Table 3) . No association was found in distribution of Arg/Gly16 and Gln/Glu27 polymorphisms between lung function, GOLD classification and exacerbation rates (data not shown).
Discussion
Polymorphisms in the ß2-adrenoceptor gene occur commonly in the human population and have been associated with a number of asthma phenotypes [Zhang et al. 2007; Choudhry et al. 2005; Lima et al. 1999; Ramsay et al. 1999; Dewar et al. 1998; Weir et al. 1998; Hall et al. 1995; Turki et al. 1995; Martinez et al. 1997 ]. Because similar reports in COPD patients are rare, the aim of our study was to investigate (1) the frequency of these ß2-adrenoceptor polymorphisms in COPD subjects in comparison to the healthy population and (2) the association of these polymorphisms with COPD disease severity and exacerbation rate. To our knowledge, this is the first study evaluating the role of ß2-adrenoceptor in COPD in a European Caucasian cohort.
In our study, the distribution of genotype frequency of homozygote Arg/Arg16 in COPD patients was significantly lower than in the healthy population whereas we did not find any correlation to GOLD severity stages and exacerbation frequency. In a Chinese population, Ho et al. [2001] found that the Arg16 polymorphism was also less prevalent in COPD patients than in healthy population, which is consistent with our results. Therefore the presence of the polymorphism of Gly16 may increase the patient's susceptibility to COPD development. However, Joos et al. [2003] found no association of the Arg!Gly polymorphism at position 16 to the rate of decline in lung function, bronchial hyper-responsiveness or bronchodilator response in smokers. Once only smokers with normal lung function (FEV 1 470% predicted) were included, these findings do not contradict our results obtained in COPD patients [Hegab et al. 2004] .
The advantage of our study is that we investigated patients only from the city of Leipzig and Figure 3 . Genotype frequency Arg/Arg16 was found less frequent in COPD patients than in healthy smokers, whereas Gly/Gly 16 prevailed compared to healthy smokers (p ¼ 0.026 with Fisher's exact test). its vicinity, a former GDR city with low fluctuation in the population since at least two generations. In contrast to asthma, it is difficult to perform functional studies to test the hypothesis of low ß2-agonist response in patients with a polymorphism of the ß 2 -adrenoreceptor gene once this disease is characterized and defined by low responsiveness on bronchodilators. Low responsiveness was part of our inclusion criteria primarily to correctly define COPD phenotype according to GOLD [GOLD Executive Committee, 2007] , and to exclude patients with asthma, a standard procedure in COPD trials. Therefore, although in vitro studies demonstrated that Gly16 is associated with increased agonistpromoted down-regulation of the ß2-adrenoreceptor compared with Arg16, we could not test pharmacological ß2-agonist response in vivo as done in comparable asthma studies [Tan et al. 1997; Green et al. 1994 Green et al. , 1993 . Possible impact of ß2-adrenoceptor polymorphism on the treatment in COPD patients may be less important than in asthma because COPD pathogenesis and prognosis are also influenced by numerous other factors including -among others -age, susceptibility to exogenous factors, low treatment response to inhaled corticosteroids and eventually ethnic descent [Umeda et al. 2008; Matheson et al. 2006; Ho et al. 2001] .
In contrast to polymorphism in position 16 considerable controversy relates to the association of Gln27 polymorphism and FEV1 decline. In our cohort no predominance of Gln27 polymorphism was found in COPD patients when compared with healthy smokers. Further, the occurrence of this polymorphism did not correlate with COPD severity which is in contrast to Ho et al. [2001] who described significantly higher Gln27 polymorphism rates in COPD patients with low FEV 1 . Regardless of these findings, these polymorphism rates did not differ between COPD patients and healthy controls. Hegab et al. [2004] reported a significantly higher allele frequency of Gln27/Glu27 in Egyptian and Japanese COPD patients compared with the healthy smoking control group [Hegab et al. 2004 ]. Joos et al.
[2003] suggested a protective role of heterozygosity of the Gln27 ! Glu27 polymorphism against a rapid rate of lung function decline in individuals with low responsiveness to methacholine. In our study we do not have follow-up data to back the Joos findings. All in all the importance of the role of Gln27 polymorphism for obstructive pulmonary disease is uncertain and the data -including ours -do not point to an apparent direction and may be of secondary importance for COPD as also suggested by Ho et al. [2001] . Although the polymorphism of Gln27 ! Glu27 is known for a ß2-adrenoreceptor downregulation [Tan et al. 1997; Green et al. 1994] , the linkage to the asthma phenotype is suggested to be unlikely by most authors [Summerhill et al. 2000; Ulbrecht et al. 2000; Lima et al. 1999; Dewar et al. 1998; Turki et al. 1995] . Obviously, only the Arg/Gly16 polymorphism seems to be important for ß2-agonist drug response in asthma [Taylor et al. 2002; Taylor and Kennedy, 2000 ] and regarding to our results also for COPD phenotype.
Although the airflow limitation in COPD is by definition not fully reversible, ß2-adrenergic agonists are a cornerstone in COPD treatment [GOLD Executive Committee, 2007] . Efficacy of ß2-adrenoreceptor activation is also essential for various other functions such as inhibition of airway smooth-muscle cells proliferation, stimulation of mucociliary transport, reduction of mucosal damage and inhibition of neutrophil accumulation. The ß2-adrenoreceptor polymorphisms might therefore also influence all these functions. It is also possible that other yet to be identified functions of ß2-adrenoreceptor gene may be relevant to the pathophysiology of COPD. In conclusion, the presence of allele Gly16 might be one of the genetic factors that make patients more susceptible to the risk of irreversible form of COPD development than healthy smoker.
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